For the medium/low HER2-expressing cancer cell line JIMT-1, IgG1-DE and IgG1-DE/GM had greater ADCC compared with the other variants in the 10:1 model (Fig. 5C), whereas IgG1-DE/GM trended highest in the 3:1 model (Supplementary Fig. S7). This evidence concerns the gene ERBB2 and cancer.